Your browser doesn't support javascript.
loading
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Weinblatt, Michael E; Baranauskaite, Asta; Niebrzydowski, Jaroslaw; Dokoupilova, Eva; Zielinska, Agnieszka; Jaworski, Janusz; Racewicz, Artur; Pileckyte, Margarita; Jedrychowicz-Rosiak, Krystyna; Cheong, Soo Yeon; Ghil, Jeehoon.
Afiliação
  • Weinblatt ME; Brigham and Women's Hospital, Boston, Massachusetts.
  • Baranauskaite A; Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Niebrzydowski J; Medica Pro Familia, Gdynia, Poland.
  • Dokoupilova E; Medical Plus, Uherske Hradiste, Czech Republic.
  • Zielinska A; Medica Pro Familia, Warsaw, Poland.
  • Jaworski J; Reumatika, Centrum Reumatologii, Warsaw, Poland.
  • Racewicz A; Zdrowie Osteo-Medic, Bialystok, Poland.
  • Pileckyte M; Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Jedrychowicz-Rosiak K; Mazowieckie Centrum Badan Klinicznych, Grodzisk Mazowiecki, Poland.
  • Cheong SY; Samsung Bioepis, Incheon, Republic of Korea.
  • Ghil J; Samsung Bioepis, Incheon, Republic of Korea.
Arthritis Rheumatol ; 70(1): 40-48, 2018 01.
Article em En | MEDLINE | ID: mdl-28950421
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Medicamentos Biossimilares / Adalimumab Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Medicamentos Biossimilares / Adalimumab Idioma: En Ano de publicação: 2018 Tipo de documento: Article